Trogenix unites cutting-edge technologies in genomics, oncology, immunotherapy, and gene therapy to create a revolutionary therapeutic approach via its Odysseus® platform. Using proven AAV vectors, its proprietary Synthetic Super-Enhancers (SSEs) are delivered directly to tumor cells without detection. These SSEs enable unprecedented precision in gene control, effectively revealing cancer to the body’s immune system and killing tumor cells. For any cells escaping the company's technology, its 'Trojan horse' can counter recurrence, offering potentially curative ‘one-and-done’ treatments for aggressive tumors. With the lead asset in glioblastoma entering the clinic, Trogenix is ready to transform treatment paradigms across multiple cancer types.